University of Southern California

Gaffney, Kevin J.

Rodgers, Kathleen, E.

Louie, Stan G.

Petasis, Nicos A.

Dizerega, Gere, S.

Kevin J Gaffney

Kathleen Elizabeth Rodgers

Stan G Louie

Nicos A Petasis

Gere S DiZerega

Maira Soto

Gere Stodder Dizerega

Michael Weinberg

Gere S Dizerega

Kathleen E Rodgers

Disclosed herein are methods for increasing circulating mesenchymal stem cells by administering a compound having the general formula 1 as defined herein, or a pharmaceutically acceptable salt thereof.

Methods for increasing circulating mesenchymal stem cells

Methods for treating systemic lupus erythematosus (SLE) are disclosed, based on administering to a subject with SLE an amount effective to treat the subject of a polypeptide including antiogensin 1-7 (A(1-7)), Nle3A 1-7, or a compound according to general formula.

Methods for treating systemic lupus erythematosus

Disclosed herein are compositions including cyclodextrin and Nle3-A(1-7) [Asp-Arg-Me-Tyr-Ile-His-Pro (SEQ ID NO: 1)] and their use in treating various disorders.

Cyclodextrin-Nle3-A(1-7) compositions and their use

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular disorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases.

Methods, compounds, and compositions for the treatment of angiotensin-related diseases

Described herein are compositions of alginate formulations that include water, divalent ions, and alginate cross-linked by the divalent ions, and their use for treating incisional wounds, such as intra-incisional application.

Use of alginate formulation for intraincisional drug delivery

This invention provides methods, compounds and compositions for the treatment of musculoskeletal disease, muscle dysfunction, muscle-wasting disease or disorder, including hereditary myopathy, neuromuscular disease, muscular dystrophy, muscular atrophy, drug-induced myopathy, and related disease, disorder or condition that causes a decrease in muscle strength, comprising the use of heterocyclic non-peptidic compounds that act as Mas agonists and/or mimics of angiotensin 1-7.

Methods, compounds, and compositions for the treatment of musculoskeletal diseases

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.

Growing community of inventors

Los Angeles, CA, United States of America

Kevin J Gaffney